Asan Multivessel Registry (ASAN MV)

December 28, 2025 updated by: Seung-Jung Park

Asan Medical Center Registry for Multivessel

The purpose of this study is to evaluate long-term prognoses of patients with multivessel coronary disease treated medically or surgically or percutaneously in real world practice.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

25000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

19 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with multivessel disease from 1995 in Asan Medical Center

Description

Inclusion Criteria:

  • Patients with multivessel disease from 1995 in Asan Medical Center
  • Age 19 and more

Exclusion Criteria:

  • For prospective cohort, not agreeing to participate with written informed consent form

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Other

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Multivessel
from 1995
Other: Treatment
Other Names:
  • Medically
  • Surgically
  • Percutaneously

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
composite event
Time Frame: 1year
death, myocardial infarction, stroke, revascularization
1year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Death
Time Frame: 1year
1year
Myocardial Infarction
Time Frame: 1year
1year
Stroke
Time Frame: 1year
1year
Revascularization
Time Frame: 1year
1year
Angina symptom
Time Frame: 1year
1year
Bleeding
Time Frame: 1year
1year
Re-hospitalization
Time Frame: 1year
1year
Stent thrombosis
Time Frame: 1year
by ARC(Academic Research Consortium) category
1year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Seung-Jung Park

Collaborators

CardioVascular Research Foundation, Korea

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2014

Primary Completion (Estimated)

June 1, 2030

Study Completion (Estimated)

December 1, 2030

Study Registration Dates

First Submitted

January 14, 2014

First Submitted That Met QC Criteria

January 16, 2014

First Posted (Estimated)

January 20, 2014

Study Record Updates

Last Update Posted (Estimated)

January 2, 2026

Last Update Submitted That Met QC Criteria

December 28, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AMCCV2013-15

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe